Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · PHAARMASIA LTD. · 31 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
PHAARMASIA LTD. is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, – (all audited; no estimate years)
₹ crore · consolidated
Revenue
EBITDA (ex other income)
margin %
Owners' profit
EPS, as reported (₹)
ROE % · ROCE %
Debt / equity (x)
Cash from operations
Capex
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · PHAARMASIA LTD. · 31 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 1 quarters
₹ crore
Q1 FY24
Revenue
7
Profit before tax
(0)
Net profit
(0)
EPS (₹)
(0.39)
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
Company
M.cap ₹ cr
P/E
P/B
EV/EBITDA
ROE %
ROCE %
Rev CAGR 5y %
EBITDA m. %
SUN PHARMACEUTICAL IND L
4,26,524
38.9
4.76
23.7
5.5
8.0
11.8
29.3
DIVI S LABORATORIES LTD
2,59,170
88.7
15.46
75.3
15.3
18.8
8.7
40.7
TORRENT PHARMACEUTICALS L
1,75,309
77.9
9.54
41.5
6.0
4.0
11.8
33.5
LAURUS LABS LIMITED
1,29,969
96.9
21.03
74.4
12.9
14.2
7.2
34.0
ZYDUS LIFESCIENCES LTD
1,24,301
27.8
4.20
15.9
17.3
18.0
12.4
24.1
DR. REDDY S LABORATORIES
1,12,892
40.2
2.89
18.2
3.4
4.2
12.1
19.9
CIPLA LTD
1,11,394
38.4
3.14
18.8
4.6
6.2
8.0
18.7
MANKIND PHARMA LIMITED
1,02,953
45.9
5.77
30.1
7.2
7.3
—
27.0
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
Metric
Company
Group median
Rank
Better than
EBITDA margin
(4.7)
13.8
160 of 177
10%
Market cap
55
769
146 of 184
21%
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · PHAARMASIA LTD. · 31 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
Date · filing
Category
Importance
Next day %
5-day %
12 Oct 2026 · RTA certifies SEBI Regulation 74(5) compliance for Sep 2026 quarter
compliance
minimal
—
—
29 Sept 2026 · Phaarmasia Ltd AGM 2026: All four resolutions passed with over 99.99% approval
board shareholder meetings
low
—
—
28 Sept 2026 · Trading window closed for Q2 and H1 FY27 results
4 Sept 2026 · Phaarmasia responds to BSE query on significant price movement
regulatory legal
medium
—
—
3 Sept 2026 · Phaarmasia 45th AGM notice published in newspapers on September 3, 2026
compliance
minimal
—
—
3 Sept 2026 · Phaarmasia submits FY26 Annual Report; PAT jumps to Rs 17.57 Cr
compliance
low
—
—
3 Sept 2026 · Phaarmasia 45th AGM on 25 Sep 2026 via video conferencing
board shareholder meetings
low
—
—
31 Aug 2026 · BSE seeks clarification from Phaarmasia on price movement
regulatory legal
medium
—
—
14 Aug 2026 · Phaarmasia reports Q1 FY27 net profit of Rs 33.90 lakh; income at Rs 656.46 lakh
compliance
minimal
—
—
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
Where a broker report shows
This document shows
Why
A rating (BUY / ADD / REDUCE / SELL)
A state: the latest filed quarter and the measured reactions
an event is a fact; a rating is an opinion that requires SEBI RA registration
A target price and upside
The current price and the multiples against the group
a target is a forecast; a multiple is a measurement
Estimate years marked E
More audited years; no estimates
MarketPing publishes no forecasts — your own model lives on the Models page
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
